CMS Advances Demonstration to Waive MIPS Requirements for Clinicians in Certain At-Risk Medicare Advantage Plans
FDA Approves Encorafenib/Binimetinib Combo for Advanced Melanoma with BRAF Mutation
ACCC Submits Comments to CMS on NCA for CAR T Therapy
FDA Approves Bevacizumab in Combination with Chemotherapy for Ovarian Cancer
FDA Approves Pembrolizumab for Advanced Cervical Cancer
ACCC In the Press at ASCO 2018
FDA Approves Venetoclax for CLL, Small Lymphocytic Lymphoma
American Cancer Society Updates Colorectal Cancer Screening Guideline
FDA Approves Abiraterone Acetate to Treat Metastatic Castration-Resistant Prostate Cancer
NIH Releases Annual Report to the Nation on the Status of Cancer
Decreased Survival in Clinical Trials for Some Patients Receiving Keytruda or Tecentriq as Monotherapy for Urothelial Cancer
FDA Approves Drug for Thrombocytopenia in Adults with Chronic Liver Disease
AUA Updates Guideline on Castration-Resistant Prostate Cancer
FDA Approves Biosimilar to Epoetin Alfa for Anemia
HHS Issues Formal RFI for Drug Pricing Blueprint
President Trump Unveils Blueprint to Lower Drug Prices
USPSTF Issues Final Recommendation on Screening for Prostate Cancer
FDA Approves Daratumumab for Newly Diagnosed, Transplant Ineligible MM Patients
FDA Approves Dabrafenib and Trametinib for Treatment of Thyroid Cancer
FDA Approves Kymriah to Treat Certain R/R Patients with Large B-Cell Lymphoma
CMS to Host Webinar on Participation Criteria for Year 2 of QPP
NASEM Publishes Workshop Proceedings on Cancer Survivorship Care, Health Professional Education
FDA Approves Dabrafenib and Trametinib for Treatment of Melanoma
CMS Issues Proposed FY2019 Hospital IPPS Rule
An Update from CMS on New Direction for Innovation Center
President Trump's Speech on Drug Pricing Postponed
FDA Approves Fostamatinib Tablets for ITP
FDA Approves Nivolumab and Ipilimumab for Treatment of Renal Cell Carcinoma
HHS Secretary Names New Leader of CMMI
ACS CAN Releases Report on Barriers to Enrollment in Clinical Trials